U.S. Health Secretary Robert F. Kennedy Jr.'s recent dismissal of all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a strong backlash from vaccine experts. The ousted panelists warn that the abrupt shakeup may undermine public health, reduce access to lifesaving vaccines, and increase the risk of preventable disease outbreaks.
Kennedy, a longtime vaccine skeptic, replaced the committee with eight new appointees, some of whom have publicly questioned vaccine safety. The decision was made just two days after the firings on June 9, 2025. In a joint article published in the Journal of the American Medical Association (JAMA), the former ACIP members expressed alarm over what they described as a destabilizing and unjustified overhaul.
They argue that the move, along with cuts to CDC immunization staff, weakens the national vaccine program and threatens decades of progress. “These decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy,” the experts wrote. They emphasized the potential risk to public trust and the safety of families across the country.
Kennedy claimed the firings were necessary to eliminate alleged conflicts of interest among the previous panel members, many of whom were appointed during the Biden administration. However, he provided no evidence of specific misconduct or bias.
Health professionals and scientists warn that politicizing vaccine oversight could erode confidence in health authorities and negatively impact vaccine uptake. The Department of Health and Human Services has not yet responded to media inquiries regarding the controversy.
Kennedy’s sweeping changes mark a significant shift in U.S. health policy and come amid growing concerns over misinformation and vaccine hesitancy.


California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai
Trump’s Name Appears on U.S. Institute of Peace Ahead of Rwanda–Congo Deal Signing
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Peru Moves to Declare State of Emergency at Chile Border as Migrant Tensions Rise
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Drones Spotted Near Zelenskiy’s Flight Path in Ireland Trigger Security Alert
New Orleans Immigration Crackdown Sparks Fear as Federal Arrests Intensify
Apple Alerts EU Regulators That Apple Ads and Maps Meet DMA Gatekeeper Thresholds
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 



